What does this research mean for the field?

Laquinimod does not provide meaningful clinical benefit for patients with Huntington's disease despite preclinical evidence suggesting potential therapeutic effects. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the therapeutic potential of laquinimod in Huntington's disease through preclinical and clinical evidence.

March 1, 2026

The therapeutic potential of laquinimod for Huntington's disease: A systematic review of preclinical and clinical studies.

Key Points

To evaluate the therapeutic potential of laquinimod in Huntington's disease through preclinical and clinical evidence.
Systematic review of preclinical and clinical studies on laquinimod.
Assessment of its effects on motor, inflammatory, and myelination pathways.
Evaluation of long-term safety data.
Preclinical studies indicate potential modulation of pathways related to Huntington's disease.
Clinical studies showed no meaningful clinical benefits from laquinimod.
Limited data available on long-term safety and efficacy.

Abstract

Preclinical evidence suggests laquinimod may modulate motor, inflammatory, and myelination pathways in HD; however, clinical evidence shows no meaningful benefit. Data on long-term safety remain limited. Larger, well-designed trials using standardized biomarkers are needed to clarify its therapeutic potential.

Bookmark

Cite This Study

Eissazade et al. (Wed,) studied this question.

synapsesocial.com/papers/69a3d856ec16d51705d2f13f https://doi.org/https://doi.org/10.1080/17582024.2026.2637425

Bookmark